Biologics

Patients who received intradiscal injections of SpinalCyte's new cell-based therapy CybroCell showed significantly improved disc height after six months.

Regenerative medicine company Mesoblast completed enrollment for its Phase 3 mesenchymal cell therapy trial to treat chronic low back pain due to degenerative disc disease.

The global orthobiologics market is predicted to exceed $5.52 billion in 2019, according to Transparency Market Research.

DiscGenics presented results from two preclinical studies assessing its IDCT product, a homologous, allogenic, injectable cell therapy.

Three spine surgeons from across the U.S. discuss where they see the biggest opportunities in spinal biologics and disc generation.

Aziyo Biologics launched OsteGro, an allograft bone matrix designed to support new bone growth in procedures such as hip reconstruction, bone fracture repair and spinal fusion.

Indianapolis-based orthopedic surgeon Greg Merrell, MD, treated the first U.S. patient in Cartiva's GRIP 2 study, evaluating the safety and effectiveness of the Cartiva Synthetic Cartilage Implant to treat osteoarthritis of the thumb. 

The global stem cell therapy market is projected to grow at a compound annual growth rate of 36.52 percent between 2017 and 2021, according to an analysis by Wise Guy Reports.

KICVentures acquired Amend Surgical, a company developing synthetic bioactive glass products.

Orthobiologics company Cerapedics received FDA approval to initiate a study of P-15L Peptide Enhanced Bone Graft compared to autograft in transforaminal lumbar interbody fusion surgery for degenerative disc disease.